Industry News - Ionis announced positive topline results for its antisense oligonucleotide therapy Tryngolza (Olezarsen) in the Phase 3 Essence clinical trial, significantly reducing triglyceride levels in patients after 6 months and achieving all key secondary endpoints with statistical significance [2] Company News - Health元 announced that its subsidiary LIAN SGP plans to acquire 64.81% of Vietnamese listed company Imexpharm for approximately 15.87 million RMB, which is a leading pharmaceutical company in Vietnam with products that include antibiotics and cardiovascular drugs, showing high synergy with Health元's existing products [3] - 众生药业 reported that its subsidiary 众生睿创's innovative drug Angladiwe tablets received approval from the National Medical Products Administration, being the first global RNA polymerase PB2 protein inhibitor for treating adult patients with uncomplicated influenza A [3] - 科伦药业 announced that its subsidiary 科伦博泰's new indication application for the ADC drug sac-TMT has been accepted by CDE, aimed at treating adults with HR+ and HER2- breast cancer who have previously received endocrine therapy and other systemic treatments [3] - 艾力斯 announced that its KRASG12C inhibitor, citric acid gorasetinib tablets, has received approval from the National Medical Products Administration for treating adult patients with advanced non-small cell lung cancer with KRASG12C mutations who have received at least one systemic treatment [4]

Group 1 - The core viewpoint is that the innovative pharmaceutical sector is experiencing sustained growth, driven by "innovation + internationalization" trends, supported by policies and increasing global competitiveness [2] - The Innovative Pharmaceutical ETF (560900) has shown strong performance, with a 4.06% increase over the past week, and notable gains in constituent stocks such as Zhongsheng Pharmaceutical (10.02%) and Kelun Pharmaceutical (6.09%) [1] - Hengrui Medicine's debut on the Hong Kong stock market saw a significant opening increase of 29.4%, raising approximately HKD 9.9 billion, with plans to allocate 75% for R&D and 15% for expanding production facilities [1] Group 2 - The innovative pharmaceutical industry chain is showing signs of fundamental improvement, with recovery in overseas orders and performance, and domestic demand expected to rebound in 2025 [2] - The medical device sector is also anticipated to improve in 2025, alongside the emergence of AI in healthcare, which is expected to bring new changes to the pharmaceutical industry [2] - Morgan Asset Management is integrating its global technology investment products to help investors capitalize on opportunities in quality technology companies amid a new wave of technological advancements [2][3]

Group 1 - The core viewpoint of the article highlights the strong performance of innovative pharmaceutical stocks, with Zhongsheng Pharmaceutical hitting the daily limit up [1] - Other pharmaceutical companies such as Haitian Pharmaceutical, Huason Pharmaceutical, Chengda Pharmaceutical, Hongri Pharmaceutical, Huahai Pharmaceutical, Tonghua Dongbao, and Shanghai Kaibao also experienced significant gains [1] - The news mentions that Heng Rui Pharmaceutical plans to issue 225 million shares in Hong Kong, with its stock price rising over 30% on the first day of trading [1]

Group 1 - A-share pharmaceutical stocks are active at the beginning of trading, with Zhongsheng Pharmaceutical and Haisen Pharmaceutical hitting the daily limit [1] - Haichen Pharmaceutical, Huason Pharmaceutical, Taiji Group, and Duori Pharmaceutical also experienced gains [1]

证券代码：002317 公告编号：2025-051 广东众生药业股份有限公司 一、药品研发及相关情况 甲型流感传染性强，常引起季节或局部爆发流行，甚至是世界大流行。昂拉 地韦片是具有明确作用机制和全球自主知识产权的一类创新药物，用于成人单纯 性甲型流感患者的治疗。 昂拉地韦片 III 期临床试验结果提示，与安慰剂组相比，昂拉地韦组在主要 终点指标七项流感症状缓解时间（TTAS）、次要终点指标包括单系统或单症状 指标缓解时间、病毒学指标（如病毒载量下降、病毒转阴时间、病毒转阴受试者 比例）等均优于安慰剂组，达到统计学显著性差异。昂拉地韦片也是国内唯一一 个与奥司他韦头对头开展 III 期临床试验并获批上市的抗流感药物，昂拉地韦组 在中位 TTAS 和发热缓解时间均比奥司他韦组缩短了近 10%。 体外病毒学研究表明，昂拉地韦对多种甲型流感病毒的抑制能力显著优于神 经氨酸酶抑制剂奥司他韦以及核酸内切酶抑制剂玛巴洛沙韦，并且对于奥司他韦 耐药的病毒株、玛巴洛沙韦耐药的病毒株和高致病性禽流感病毒株均具有很强的 抑制作用。 第 1 页 共 2 页 证券代码：002317 公告编号：2025-051 关于昂拉地韦片获得国家 ...

Core Viewpoint - The approval of ZHONGSHENG Pharmaceutical's Angladiwe Tablets by the National Medical Products Administration marks a significant advancement in the treatment of influenza, being the first RNA polymerase PB2 protein inhibitor globally [1] Company Summary - ZHONGSHENG Pharmaceutical (002317) announced the approval of Angladiwe Tablets on May 22, 2025, for the treatment of adult uncomplicated influenza A patients [1] - Angladiwe Tablets are the only antiviral drug in China that has undergone head-to-head Phase III clinical trials against Oseltamivir and received market approval [1] Clinical Trial Results - Phase III clinical trial results indicated that Angladiwe Tablets significantly outperformed the placebo group in seven primary endpoints related to the relief of influenza symptoms, achieving statistical significance [1] - The Angladiwe group demonstrated a nearly 10% reduction in median time to alleviation of total symptoms (TTAS) and fever relief compared to the Oseltamivir group [1]

Core Viewpoint - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has announced its 2024 annual profit distribution plan, which includes a cash dividend of 170,311,295.40 yuan, approved by the shareholders' meeting on May 19, 2025 [1]. Summary by Sections 1. Profit Distribution Plan - The company will distribute a cash dividend of 2.00 yuan per 10 shares (including tax) to all shareholders, based on a total share capital of 851,556,477 shares [1]. - For specific investors, such as those holding shares through the Hong Kong market or certain institutional investors, the cash dividend will be adjusted to 1.80 yuan per 10 shares [1]. 2. Shareholder Registration and Ex-Dividend Dates - The record date for the profit distribution is set for May 28, 2025, and the ex-dividend date is May 29, 2025 [2]. 3. Distribution Method - Cash dividends will be directly credited to shareholders' accounts through their securities companies or other custodians [2]. 4. Consultation Information - The company provides contact details for inquiries regarding the profit distribution, including a contact person and phone number [2]. 5. Additional Notes - The company will not withhold individual income tax for certain shareholders at the time of distribution, with tax obligations calculated based on the holding period when shares are sold [1].

1、公司 2024 年度权益分派方案为：以公司 2024 年 12 月 31 日总股本 851,556,477 股为基数，向全体股东每 10 股派发现金红利 2.00 元（含税），不送 红股，不以公积金转增股本，共计派发现金红利 170,311,295.40 元，剩余未分配 利润滚存至下一年度。 2、在权益分配实施前，如因可转债转股、股份回购、股权激励行权等原因 导致总股本发生变动的，公司将按照"分配比例不变，调整分配总额"的原则， 对现金分红总额进行相应调整。由于公司正在实施限制性股票激励事项，公司报 告期末至权益分派股权登记日期间可参与利润分配的股本发生变动，则以权益分 派股权登记日可参与利润分配的总股本为基数，按每 10 股派发现金红利 2.00 元 （含税）为原则，调整派发现金红利总额。 3、本次实施的分配方案与股东大会审议通过的分配方案一致，本次实施分 配方案距离股东大会审议通过的时间未超过两个月。 证券代码：002317 公告编号：2025-050 广东众生药业股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大 ...

证券代码：002317 公告编号：2025-049 广东众生药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 第八届董事会第二十次会议、第八届监事会第二十次会议及于 2025 年 5 月 19 日 召开公司 2024 年年度股东大会，审议通过了《关于 2022 年限制性股票激励计划 第三期解除限售条件未成就暨回购注销部分限制性股票的议案》。 根据《2022 年限制性股票激励计划(草案)》 证券代码：002317 公告编号：2025-049 特此公告。 广东众生药业股份有限公司董事会 二〇二五年五月十九日 第 2页 共 2页 规定，公司 2024 年业绩未能达到激励计划第三期解除限售条件的业绩考核要求， 激励计划第三期解除限售条件未成就。公司决定回购注销激励计划授予但尚未解 除限售的 72 名激励对象的第三个解除限售期对应的 162.60 万股限制性股票，占 目前公司股本总额的 0.19%。回购价格为 4.98 元/股。具体内容详见公司于 2025 年 4 月 2 ...

证券代码：002317 公告编号：2025-049 广东众生药业股份有限公司 关于回购注销部分限制性股票的减资公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 第八届董事会第二十次会议、第八届监事会第二十次会议及于 2025 年 5 月 19 日 召开公司 2024 年年度股东大会，审议通过了《关于 2022 年限制性股票激励计划 第三期解除限售条件未成就暨回购注销部分限制性股票的议案》。 根据《2022 年限制性股票激励计划(草案)》（以下简称"激励计划"）等相关 规定，公司 2024 年业绩未能达到激励计划第三期解除限售条件的业绩考核要求， 激励计划第三期解除限售条件未成就。公司决定回购注销激励计划授予但尚未解 除限售的 72 名激励对象的第三个解除限售期对应的 162.60 万股限制性股票，占 目前公司股本总额的 0.19%。回购价格为 4.98 元/股。具体内容详见公司于 2025 年 4 月 26 日、2025 年 5 月 20 日刊载在《证券时报》和巨潮资讯网 ...